An observational study in Early Memory Loss, Mild Cognitive Impairment and Alzheimer's Disease, sponsored by Pamlab, Inc.. Completed at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-09.
Sponsored by Pamlab, Inc. (part of Alfasigma S.p.A.) · Observational
Among 224 studies in Memory Disorders with a site in United States — 34 open to participants now, 51 under way, none of them phase 3. Memory Disorders · United States.
Among the 224 studies in Memory Disorders with a site in United States, this one is the 15th largest by enrollment of the 33 observational ones that give a count, is one of 7 that started in 2011, is one of 33 observational ones, and was the 63rd registered.
373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.
Browse Memory Disorders studies →34 of the 224 studies in Memory Disorders with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
University of Texas at Austin · Sites in United States
Ages 18–90 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 60–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Memory Disorders studies recruiting now, 27 (50%) set no upper age limit and 13 (24%) stop at 75 or younger; 3 take children under 18; 22 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
224 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 33 · Phase 3 13 · Phase 4 10
First in 1995; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is close to the median of 187 across 62 observational studies indexed under Memory Disorders.
Median enrollment 68 across the 186 interventional studies, 197 across the 33 observational. Of the 159 that completed or were terminated, 49 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 224 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pamlab, Inc., one of the names counted as Alfasigma S.p.A.. Under that name alone:
Pamlab, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Alfasigma S.p.A. has 1 study filed under Memory Disorders — fewer than ten, so there is no comparison to draw.
16 of the studies in Memory Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06391489Dartmouth-Hitchcock Medical CenterHOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS) | 2026-12 |
| NCT03896529Georgia Institute of TechnologyNeurobiological Mechanisms of Aging and Stress on Prospective Navigation | 2026-12-25 |
| NCT05027789University of California, DavisBrain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention | 2026-12-31 |
| NCT05611918Johns Hopkins UniversityREpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study | 2026-12-31 |
| NCT05661084Hebrew SeniorLifeNon-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 224 studies in Memory Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be an observational study in which patients who have been prescribed CerefolinNAC® are invited to participate in surveys regarding their experiences with CerefolinNAC®. CerefolinNAC® is a medical food indicated for the distinct nutritional requirements of individuals under treatment for early memory loss with particular emphasis for those individuals diagnosed with or at risk for neurovascular oxidative stress and/or hyperhomocysteinemia; mild to moderate cognitive impairment with or without vitamin B12 deficiency, vascular dementia or Alzheimer's disease. The purpose of this study is to increase the understanding of the role of CerefolinNAC® in managing proper neuronal function in the brain, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for early memory loss.
Surveys used to conduct this study will be administered via telephone by InfoMedics, Inc., a company with an established system for developing such patient-physician feedback programs. Participating physicians will ask their patients to participate in the program after CerefolinNAC® has been prescribed and provide them with a brochure containing an introduction to the program and instructions on how to enroll. Patients self-enroll, take a brief survey before starting their CerefolinNAC® prescription, and then two brief follow-up surveys at 6 weeks and 12 weeks. As patients complete surveys within the study, their physician will receive individualized feedback reports outlining their patient's treatment experience and progress. Patients will also receive a copy of their own reports, to help encourage them to continue taking CerefolinNAC® as directed. Patients will also receive educational materials about managing their early memory loss.
Patients with Early Memory Loss Who Have Been Prescribed CerefolinNAC®
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
Other: CerefolinNAC®
CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
To determine if CerefolinNAC® affects a subject's quality of life as measured by the Quality of Life-Alzheimer's Disease Scale (QOL-AD)
The QOL-AD is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life.
Time frame: Baseline, Week 6 and Week 12
To determine overall patient satisfaction with CerefolinNAC® using a 9-point satisfaction scale
Time frame: Weeks 6 and 12
The record gives a start of May 2011, a primary completion of Nov 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.